ENVB Enveric Biosciences Inc
14,223
$0.84
$0.06
(6.67%)
| Watchers | 14,223 |
| 52-Wk Low | $0.649 |
| 52-Wk High | $6.98 |
| Market Cap | $6.51M |
| Volume | 210,204.00 |
| 52-Wk High | $6.98 |
| 52-Wk Low | $0.649 |
'Psychedelics-Inspired' Meds For Depression, Anxiety, Addiction Producer Trims Q1 Net Loss YoY, Increases Cash On HandBenzinga • 2 days ago
Enveric Biosciences reported on Wednesday financial results for the first quarter of 2024 ended March 31, 2024.'We believe the first quarter of 2024 was a highly productive period for Enveric as the...
Share to Feed
Enveric Biosciences (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of...
Enveric Biosciences (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of...
Enveric Biosciences, Inc (NASDAQ: ENVB), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and...
FibroGen, Acorda Therapeutics, Enveric Biosciences among healthcare movers...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
ENVB stock results show that Enveric Biosciences beat analyst estimates for earnings per share the fourth quarter of 2023.
The post ENVB...
Enveric Biosciences, Inc. (NASDAQ:ENVB - Get Free Report) was the recipient of a large increase in short interest during the month of March. As of March 15th, there was short interest totalling...
Enveric Biosciences, Inc. (NASDAQ:ENVB - Get Free Report) was the recipient of a large growth in short interest during the month of March. As of March 15th, there was short interest totalling 150,400...
Enveric Biosciences (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of...
Enveric Biosciences (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of...